 Current status cyclosporin treatment membranous IgA membranoproliferative glomerulonephritis effects cyclosporin CyA Sandimmun therapy various types primary glomerular diseases membranous nephropathy data positive effect disorder control risk-benefit ratio need adjunctive therapy steroids terms time response duration response risk nephrotoxicity needs functional pathological perspective Proper prospective trials safety efficacy CyA disease IgA membranoproliferative glomerulonephritis data sparse isolated studies benefit categories risks evident careful pilot studies conclusions regards use agent disorders